Breast Care最新文献

{"title":"Effects of Continuous Care Combined with Dietary Care on Sleep Quality and Quality of Life in Patients with Breast Cancer Fatigue.","authors":"Zhining Yu, Li Song, Xingrui Wei, Lifang Wang, Liping Cui","doi":"10.1159/000548024","DOIUrl":"10.1159/000548024","url":null,"abstract":"<p><strong>Objective: </strong>Patients with breast cancer fatigue-related fatigue have significantly reduced sleep quality and quality of life. Continuous care combined with dietary care has been shown to improve sleep quality and quality of life in patients with malignant tumor. However, its effects on breast cancer patients undergoing radiotherapy have not been fully explored.</p><p><strong>Methods: </strong>Eighty breast cancer patients with fatigue were treated in our hospital from April 2020 to June 2022 and randomly divided into a control group (<i>n</i> = 40) and an observation group (<i>n</i> = 40). The control group received routine nursing care, while the observation group received continuous nursing combined with dietary nursing. Sleep quality, quality of life, compliance behavior, and nursing satisfaction were compared between the two groups.</p><p><strong>Results: </strong>The Pittsburgh Sleep Quality Scale scores of both groups were lower after intervention than before, and the observation group's Pittsburgh Sleep Quality Index was lower than that of the control group (<i>p</i> < 0.05). After intervention, Generic Quality Of Life Inventory-74 scores of both groups were higher than before intervention, and the observation group's score was higher than the control group (<i>p</i> < 0.05). The reasonable diet rate, treatment compliance rate, regular follow-up rate, and regular lifestyle in the observation group were significantly higher than those in the control group (<i>p</i> < 0.05). The nursing satisfaction of the observation group was 95.00%, significantly higher than that of the control group (80.00%, <i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Continuous nursing combined with dietary nursing can significantly improve sleep quality and quality of life, as well as improve compliance behaviors and nursing satisfaction of patients with breast cancer fatigue, indicating significant clinical value.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"49-57"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Sentinel Lymph Node Biopsy with Blue Dye Only after Neoadjuvant Systemic Treatment in Patients with Breast Cancer Who Had Biopsy-Proven Node-Positive Disease at Admission: SENATURK-ROSANNA Study.","authors":"Aysegul Aktas, Meryem Gunay Gurleyik, Guldeniz Karadeniz Cakmak, Hasan Karanlik, Sibel Ozkan Gurdal, M Umit Ugurlu, Atakan Sezer, Bahadir M Gulluoglu","doi":"10.1159/000548046","DOIUrl":"10.1159/000548046","url":null,"abstract":"<p><strong>Introduction: </strong>In breast cancer patients with initially metastatic axillary lymph nodes (pN+, ALNs), neoadjuvant systemic treatment (NST) significantly downstages axillary disease. Sentinel lymph node biopsy (SLNB) in well-responded patients has been associated with high false-negative rates (FNRs) when less than 3 nodes are retrieved and a single tracer is used. Targeted axillary dissection after node clipping has been proposed to reduce FNR but is costly, is labor intensive, and requires specialized equipment. However, there is limited evidence linking high FNR with worse long-term oncological outcomes, such as recurrence rates. This study evaluates axillary recurrence rates in breast cancer patients downstaged by NST and assessed with SLNB using blue dye alone.</p><p><strong>Methods: </strong>We retrospectively analyzed clinical, pathological, and follow-up data from 245 breast cancer patients treated between 2010 and 2021 across six centers in Turkiye. All patients had pN+, ALNs at diagnosis and were downstaged to ypN0 or ypN0[i+] by SLNB with blue dye after NST. Recurrence rates in the breast, axilla, other regional lymphatics, distant organs, and mortality were recorded.</p><p><strong>Results: </strong>Of the 245 patients, 10% had cN2 disease and 35% had less than 3 sentinel lymph nodes retrieved. After SLNB, 6% had isolated tumor cells in their nodes, while the rest achieved a pathologic complete response. The median follow-up was 51 months. Only 2% developed ipsilateral axillary recurrence (0.8% isolated), and 18% had any recurrence, primarily as distant metastasis. The mortality rate was 9%.</p><p><strong>Conclusion: </strong>Our study demonstrates that performing SLNB after NST using only blue dye may be a viable and acceptable approach in clinical practice. The oncological safety and adequacy of this simple method should be confirmed with further studies.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"58-67"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Experience of Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in a Real-World Setting: European Patients' Perspectives.","authors":"Maggie Banys-Paluchowski, Diana Lüftner, Agnieszka Korfel, Nadia Chouaki, Isaac Sanderson, Sophie G Barlow, Alex Rider, Astra M Liepa, Christian Jackisch","doi":"10.1159/000547748","DOIUrl":"10.1159/000547748","url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluated the experiences of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer (EBC) in France, Germany, Italy, Spain, and the UK, including satisfaction with how well they are coping with their EBC, their wellbeing, knowledge and awareness of their disease, symptoms of treatment, and factors associated with coping.</p><p><strong>Methods: </strong>Data were collected cross-sectionally using a real-world, multinational, point-in-time observational study (2019 Adelphi EBC Disease Specific Programme^™ [DSP]) during June-October 2019. Physicians who manage/treat EBC completed online patient record forms (PRFs) and their patients were asked to complete a paper-based voluntary patient self-completion (PSC) form. Regression analyses were used to identify factors associated with coping with EBC.</p><p><strong>Results: </strong>Of 1,859 patients with PRFs, 925 (49.8%) completed a PSC and were the focus of this analysis. The majority (69.9%) of patients reported being satisfied with their coping with EBC and reported overall mean Functional Assessment of Cancer Therapy-Breast scores (scale 0-28) of 21.6 for physical wellbeing and 14.4 for functional wellbeing. Most patients (87.3%) reported being informed about at least one disease characteristic. Half of patients reported being actively involved in their breast cancer treatment decisions, although some patients (23.1% overall) reported being involved in these decisions, but they did not want to be. Physicians were a source of information on breast cancer for 89.9% of patients. Patients reported a wide range of symptoms, and 68.6% of patients reported that EBC had affected their ability to work. Ability to work (including work at home) was also the only actionable factor clearly associated with positive coping in our regression analysis. Significant differences among countries were found for almost all aspects evaluated.</p><p><strong>Conclusion: </strong>Most patients were satisfied with how well they were coping, which is encouraging. Despite the overall symptom burden, high health-related quality of life (HRQoL) was generally maintained, providing reassurance that adjuvant treatment approaches can be administered without detrimental effects on HRQoL. Joint decision-making may help some patients, but others may prefer less involvement in treatment decisions. Helping patients continue employment may be beneficial from both a personal and an economic perspective.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"21 1","pages":"41-48"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12908957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Therapy on Health-Related Quality of Life in Breast Cancer Patients >60 Years.","authors":"Maximiliane Burgmann, Valerie Schlager, Annika Lotz, Kerstin Hermelink, Thomas Kolben, Christina Seifert, Franziska Ganster, Sven Mahner, Nadia Harbeck, Rachel Wuerstlein","doi":"10.1159/000547600","DOIUrl":"10.1159/000547600","url":null,"abstract":"<p><strong>Introduction: </strong>Since the risk of developing breast cancer (BC) increases with age, it is primarily a challenge for the older population. Older patients are often affected by comorbidities and frailty. The aim of this study was to determine the impact of adjuvant therapy on quality of life in older BC patients, considering their global health status including comorbidities.</p><p><strong>Methods: </strong>All BC patients aged 60 years old and above at initial diagnosis, who had been treated at the Breast Center of the LMU University Hospital of Munich, Germany, between 2010 and 2013, were eligible for participation. Quality of life was assessed by validated questionnaires. With a self-developed questionnaire, we assessed patients' general health status, oncological therapy as well as the Barthel Index and Charlson Comorbidity Index (CCI) as instruments of the geriatric assessment.</p><p><strong>Results: </strong>Data collected from 276 patients were included. Health-related quality of life (HRQoL) was affected by chemotherapy in the areas of physical function, mobility, fatigue, burden of disease, and financial difficulties. Regarding endocrine therapy, HRQoL was only affected in the area of burden of disease. A higher CCI and BMI as well as polymedication were significantly correlated with worse HRQoL.</p><p><strong>Conclusion: </strong>This cross-sectional, retrospective analysis indicates that chemotherapy affects HRQoL negatively in several quality of life areas in the first 3 years after the initial diagnosis of BC. CCI, obesity, and polymedication also impact on HRQoL. This knowledge should be incorporated into the treatment decision-making process and targeted measures should be offered to support older patients.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"28-40"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000549718","DOIUrl":"10.1159/000549718","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000548681.].</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"82"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Levonorgestrel-Releasing Intrauterine Devices on Magnetic Resonance Imaging of the Breast.","authors":"Jenny Müller, Marc Körnig, Monika Farkas, Kelly Reeve, Dusan Pisarcik, Rahel A Kubik-Huch, Cornelia Leo","doi":"10.1159/000547544","DOIUrl":"10.1159/000547544","url":null,"abstract":"<p><strong>Introduction: </strong>Levonorgestrel-releasing intrauterine devices (LNG-IUD) are well established as both contraceptives and for the treatment of hypermenorrhoea. While progestogenic effects are mainly localised in the uterine cavity, levonorgestrel also confers a systemic influence, including on breast tissue. Current research suggests that there is an increase in background parenchymal enhancement (BPE) in magnetic resonance imaging (MRI) for patients with an LNG-IUD.</p><p><strong>Methods: </strong>This retrospective study analyses MRIs of premenopausal women. Patients using an LNG-IUD (<i>n</i> = 30) were matched with 2 control patients without an LNG-IUD, based on age. MRI reports were evaluated for BI-RADS classification, non-mass enhancement, fibroglandular tissue, BPE, and the presence of foci. In addition, two experienced radiologists independently assessed the MRI scans (<i>n</i> = 90) in a blinded setting, evaluating BPE and diagnostic confidence.</p><p><strong>Results: </strong>The results from the blinded evaluation by the radiologists showed a significant difference for BPE and interpretability between the two groups (<i>p</i> = 0.002 and 0.003, respectively). The odds of higher BPE for subjects with an IUD were 3.9 (95% CI: 1.69-9.37) compared to the control group. The odds of lower image interpretability for the IUD group were 3.48 (95% CI: 1.54-8.14) relative to the control group.</p><p><strong>Conclusion: </strong>The increased BPE in breast MRIs due to the use of an LNG-IUD potentially leads to limited diagnostic confidence. Women should be appropriately counselled regarding their contraceptive choices, given that MRI is often the preferred imaging modality for women with a high risk for developing breast cancer.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"10-17"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose Comparison (1 mL versus 2 mL) of Superparamagnetic Tracer for Sentinel Node Biopsy in Early Breast Cancer: Real-World Analysis from 456 Patients.","authors":"Ina Shehaj, Amelie Löwe, Paul Löwe, Anne-Sophie Heimes, Antje Lebrecht, Kathrin Stewen, Marcus Schmidt, Annette Hasenburg, Slavomir Krajnak","doi":"10.1159/000550609","DOIUrl":"10.1159/000550609","url":null,"abstract":"<p><strong>Background: </strong>Superparamagnetic iron oxide (SPIO) tracers offer a radiation-free technique for sentinel lymph node biopsy (SNB) in early breast cancer (eBC). However, the data on optimal administration in daily practice, such as the optimal tracer volume and injection method, are still lacking.</p><p><strong>Methods: </strong>In this real-world data analysis, patients with clinically node-negative eBC who underwent SNB with SPIO (Magtrace®) between January 2020 and December 2022 were included. Primary endpoint was the impact of tracer volume on the detection rate. Secondary endpoints evaluated number of removed sentinel lymph nodes, surgical time, and the impact of tracer timing and body mass index (BMI) on detection rate.</p><p><strong>Results: </strong>A total of 456 patients were included in the study. Overall, 223 patients received 1 mL and 232 patients 2 mL of SPIO. The median time of tracer application was 4 days. Detection rates were similar between both groups (95.5% for 1 mL vs. 96.1% for 2 mL; <i>p</i> = 0.707), with a median of 2.0 sentinel nodes removed in both groups (<i>p</i> = 0.205). The median time of surgery was 70 min in the 1 mL group and 72 min in the 2 mL group, <i>p</i> = 0.972. The detection rate was 97.3% and 95.3% when tracer was injected before and after the median time of application, respectively (<i>p</i> = 0.286). BMI of ≥25 kg/m² led to a detection rate of 94.9% in the 1 mL group and 94.2% in the 2 mL group (<i>p</i> = 0.520).</p><p><strong>Conclusions: </strong>In this large real-world analysis, 1 mL and 2 mL were similar in the clinical performance of SNB in eBC. High detection efficacy was found regardless of tracer timing and BMI. This real-world analysis reinforces SPIO's role as an effective and adaptable alternative to conventional tracers in SNB for eBC.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12995379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity and Reliability Study of the Turkish Version of the Breast Cancer Stigma Scale: A Methodological Study.","authors":"Nurten Şişman, Zeynep Erdogan","doi":"10.1159/000550063","DOIUrl":"10.1159/000550063","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this methodological and descriptive study was to conduct the validity and reliability study of the Breast Cancer Stigma Scale (BCSS) for the Turkish population of breast cancer patients.</p><p><strong>Methods: </strong>The sample of the study consisted of 150 female patients who were diagnosed with breast cancer, met the inclusion criteria, and applied to the oncology clinics and outpatient units of a university hospital. Data were collected through face-to-face interviews using a 13-item personal information form investigating patients' sociodemographic and disease-related characteristics, the BCSS, and the Patient Health Questionnaire-9 (PHQ-9). Language and content validity, criterion validity, construct validity, and reliability analyses of the scale were conducted sequentially. Descriptive statistical methods (number, percentage, mean, standard deviation), correlation analysis, Kruskal-Wallis test, Mann-Whitney U test, <i>t</i>-test, Cronbach's alpha analysis, confirmatory factor analysis, and exploratory factor analysis were used for data analysis.</p><p><strong>Results: </strong>The content validity index (CVI) value was found to be 1.0. The factor loadings of the scale ranged between 0.663 and 0.892, and the total explained variance was 73.89%. The Turkish version of the BCSS demonstrated excellent internal consistency (Cronbach's α = 0.70-0.92) and good construct validity (CFA fit indices: CFI = 0.97, TLI = 0.96, RMSEA = 0.05, SRMR = 0.05). The Cronbach's alpha coefficients for the subscales of the BCSS were 0.92 for the Body-Image Impairment (BI) subscale, 0.70 for the Social Isolation (SI) subscale, 0.78 for the Discrimination (D) subscale, 0.89 for the Internalized Stigma (IS) subscale, and 0.90 for the total the BCSS score. The Turkish version of the scale showed a good fit with the original model, confirming its four-factor structure.</p><p><strong>Conclusion: </strong>The Turkish version of the BCSS was found to be valid and reliable.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12978814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147442816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Discussion: ABC8, Bridging the Gap.","authors":"Rachel Wuerstlein, Eva Schumacher-Wulf, Volkmar Müller, Orit Kaidar-Person, Renate Haidinger, Joana Mourato Ribeiro, Shani Paluch-Shimon","doi":"10.1159/000550030","DOIUrl":"10.1159/000550030","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12851627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABC8 Consensus: Assessment by a German Group of Experts.","authors":"Nina Ditsch, Michael Untch, Peter A Fasching, Susanne Briest, Johannes Ettl, Renate Haidinger, Diana Lüftner, Christian Maurer, Volkmar Müller, Tjoung-Won Park-Simon, Eugen Ruckhäberle, Christian Schem, Eva Schumacher-Wulf, Nadia Harbeck, Rachel Wuerstlein","doi":"10.1159/000550147","DOIUrl":"10.1159/000550147","url":null,"abstract":"<p><strong>Background: </strong>The \"International Consensus Conference for Advanced Breast Cancer\" was initiated with the rationale to standardize treatment of advanced breast cancer (ABC) based on available evidence. The aim was to ensure that all ABC patients worldwide receive adequate treatment and get access to new diagnostic, therapeutic, and supportive options.</p><p><strong>Topics of abc8: </strong>Since the beginning ABC Consensus Conference has been organized in Lisbon/Portugal. The 8th International Consensus Conference for ABC (ABC8) took place there from November 4th to 8th, 2025, and focused not only on metastatic disease but also on locally advanced and inflammatory breast cancer (BC). Special topics were new drugs and new therapies with promising results in randomized clinical trials. Not all of them are currently approved by FDA (Food and Drug Administration) or EMA (European Medicines Agency) for the indication in which the study was conducted. As in previous years, patient advocates from around the world were integrated into the ABC Conference and contributed substantially to the consensus.</p><p><strong>Rationale for the manuscript: </strong>A German BC expert panel comments on the voting results of the ABC8 panelists regarding their relevance for routine clinical practice in Germany. As with previous meetings, the ABC8 votes focused on modified or new statements. Statements not modified for the ABC8 consensus remain valid. The German comments are always based on the current recommendations of the \"Breast Committee\" of the Gynecological Oncology Working Group (Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Mamma).</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12851628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}